RECOVER/ARVIN-GOODS
15.2.2024 13:01:29 CET | Business Wire | Press release
Arvin Goods, the Seattle-based responsible apparel brand, has announced the release of its latest sock collection, crafted from Recover™ recycled cotton fiber. Since launching in 2019, the company has been at the forefront of sustainable fashion and is one of the few brands in the market utilizing recycled materials for its entire collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215745837/en/
(Photo: Arvin Goods)
The latest launch features crew socks made from 79% recycled materials, including 43% recycled polyester and 36% Recover recycled cotton fiber. Recover’s proprietary recycled fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel supply chain. Manufacturing just one pair of Arvin Goods socks made with 36% Recover fiber saves up to 18 gallons of water compared to a pair made with conventional cotton.
Boris Mercier, SVP Marketing at Recover, said, “Our ongoing work with Arvin Goods was born out of a shared belief in the importance of circular fashion that never sacrifices quality, feel, or style. As the ingredient brand of reference in recycled cotton, we aim to educate consumers to make more conscious choices and accelerate the adoption of sustainable initiatives within the casual wear segment.”
For each pair of socks, responsibility is the core of Arvin’s approach to the design, manufacturing, and distribution. As well as using low-impact impact recycled materials, responsibility was also prioritized in the value chain. Thanks to Recover’s strategic partnership with Ferre Yarns, based locally in Alicante, Spain the impact of transportation was also minimized.
Dustin Winegardner, Managing Partner at Arvin Goods, commented, “We have been working with Recover™, and the Ferre family of yarns since the beginning of Arvin Goods. Making it official like this and stamping the R on our packaging is an exciting step for our brand. Being able to source materials in Spain, and manufacture nearby in Portugal moves us further in our mission to deliver The Cleanest Basics on the Planet.”
Paqui Ferre, Sales and Marketing Director at Ferre, also commented, “Ferre has been working with Arvin Goods since the beginning of its history. In a clear commitment to sustainability, Arvin makes products using our most iconic yarn, FBlue. Consistent with our brand vision, FBLUE 100% recycled yarns deliver the perfect combination of circularity, performance, and color accuracy. A blend with Recover recycled cotton that answers the global call for sustainably sourced yarns while providing inspiring colors for Arvin Goods products.”
The new collection not only exemplifies Arvin Goods' sustainable ethos but also provides customers with a stylish and comfortable choice for everyday wear. The brand continues to set a new standard for low-impact fashion, encouraging consumers to make conscious choices that positively impact the planet.
The Arvin Goods recycled fiber collection starts at $12 USD and is available to purchase through their website.
Find out more about the collaboration here.
About Arvin Goods
Established in 2019 Arvin Goods has set out to help clean up a dirty industry. By utilizing recycled base materials and minimizing the movement of materials in manufacturing they are reducing the impact of one of the world's most consumed categories. Basics.
Arvin Goods produces comfortable on-trend products, that also happen to be the lowest-impact socks in the marketplace. Arvin Goods is based in Seattle, Washington USA.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Ferre
Ferre is a fourth-generation family business with a history of more than 75 years innovating the manufacture of high-quality recycled yarns. Our open-end spin factory is based in Banyeres de Mariola (Alicante), Spain and the company, founded in 1947, has been innovating the cotton recycled spinning process ever since.
We work every day to improve our products and help our customers to maximize the full potential of our low-impact yarns, always guided for the commitment of making more with less. Ferre yarns stand out for their quality and low-impact products, bringing accurate and beautiful colours to the sustainable fashion value chain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215745837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom